Seeking Alpha
10 Jun 2026, 01:22 UTC · 23w ago
Olema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Impact · against what's priced in
The outlook for OLMA is positive based on the upcoming Phase 3 OPERA-01 readout in the fall and the expansion of its KAT6/7 inhibitor into prostate cancer. These developments represent clear catalysts and market expansion opportunities that drive potential valuation upside.
- OLMA+0.50
No priced-in read yet





